Not a million miles from what BEAM is doing. They submitted an IND for BEAM-201 (a healthy donor anti-CD7 CAR-T with TRAC, CD7, PD-1 and CD52 knockouts) to the FDA in June. But in late July, was notified that the IND was placed on clinical hold. Beyond that, they are focused on identifying the collection of multiplex base edits required to make cells fully allogeneic, with internal and external data suggesting a higher number of edits will be required to meet this goal. As a result, is not expect to nominate a second CAR-T candidate this year and anticipates providing further updates next year.
Market Data 
Markets 
AI
